The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss
Open accessAbstract
The p53 tumor suppressor is often disrupted in human cancers by the acquisition of missense mutations. We generated mice with a missense mutation at codon 172 that mimics the p53R175H hot spot mutation in human cancer. p53 homozygous mutant mice have unstable mutant p53 in normal cells and stabilize mutant p53 in some but not all tumors. To investigate the significance of these data, we examined the regulation of mutant p53 stability by Mdm2, an E3 ubiquitin ligase that targets p53 for degradation, and p16 INK4a , a member of the Rb tumor suppressor pathway. Mice lacking Mdm2 or p16 INK4a stabilized mutant p53, and revealed an earlier age of tumor onset than p53 mutant mice and a gain-of-function metastatic phenotype. Analysis of tumors from p53 homozygous mutant mice with stable p53 revealed defects in the Rb pathway. Additionally, ionizing radiation stabilizes wild-type and mutant p53. Thus, the stabilization of mutant p53 is not a given but it is a prerequisite for its gain-of-function phenotype. Since mutant p53 stability mimics that of wild-type p53, these data indicate that drugs aimed at activating wild-type p53 will also stabilize mutant p53 with dire consequences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in many situations, missense mutant p53 is expressed at high levels in tumor cells, partly due to the inability of mutant p53 to induce gene expression of MDM2,379”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [379]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“Oncogenic signals such as activating Ras mutations or increased c-Myc expression also stabilize p53 in normal cells and result in senescence or apoptosis, respectively (Hermeking and Eick 1994; Wagner et al. 1994; Serrano et al. 1997; Ferbeyre et al. 2002).”
BackgroundMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 2×
“Mdm2, a negative regulator of p53, is an E3 ubiquitin ligase that targets wild-type p53 for degradation (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997).”
BackgroundParticipation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 2×
“Mdm2, a negative regulator of p53, is an E3 ubiquitin ligase that targets wild-type p53 for degradation (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997).”
BackgroundA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 1×
“Lastly, p16 loss, a common event in human cancers (Kamb et al. 1994; Nobori et al. 1994), also stabilized mutant p53 in vivo and yielded a metastatic phenotype.”
BackgroundActivation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Activation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Cited by
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
Mutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
USP10 Regulates p53 Localization and Stability by Deubiquitinating p53
Yuan, J., Luo, K., Zhang, L., Cheville, J. C., & Lou, Z. (2010) · Cell · doi:10.1016/j.cell.2009.12.032 · Cited by 637
“Although it was thought that mutant p53 is intrinsically stable, a recent paper suggest that downregulation of Mdm2 might be one mechanism (Terzian et al., 2008).”
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Cooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 466
Self-citationThe role of mutant p53 in human cancer
Goh, A. M., Coffill, C. R., & Lane, D. P. (2011) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 398
Mdm2-mediated ubiquitylation: p53 and beyond
Marine, J.-C., & Lozano, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.68 · Cited by 354
Self-citationImproving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354
Self-citationThe Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
Zhou, G., Liu, Z., & Myers, J. N. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25592 · Cited by 343
Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 337
Self-citationLi, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
Kim, M. P., & Lozano, G. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.185 · Cited by 311
Self-citationDeubiquitinase inhibition as a cancer therapeutic strategy
D'Arcy, P., Wang, X., & Linder, S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.002 · Cited by 310
Soussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
Tumor suppressor p53 and metabolism
Liu, J., Zhang, C., Hu, W., & Feng, Z. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy070 · Cited by 300
Li, D., Marchenko, N. D., Schulz, R., Fischer, V., Velasco-Hernandez, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 297
The Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 289
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Girardini, J. E., Napoli, M., Piazza, S., Rustighi, A., Marotta, C., Radaelli, E., Capaci, V., Jordan, L., Quinlan, P., Thompson, A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.004 · Cited by 286
Self-citationTwo hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
Hanel, W., Marchenko, N., Xu, S., Xiaofeng Yu, S., Weng, W., & Moll, U. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.17 · Cited by 283
Nakayama, M., & Oshima, M. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy075 · Cited by 282
Mutant p53 protein localized in the cytoplasm inhibits autophagy
Morselli, E., Tasdemir, E., Chiara Maiuri, M., Galluzzi, L., Kepp, O., Criollo, A., Vicencio, J. M., Soussi, T., & Kroemer, G. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6751 · Cited by 277
Real-time in vivo imaging of p16Ink4a reveals cross talk with p53
Yamakoshi, K., Takahashi, A., Hirota, F., Nakayama, R., Ishimaru, N., Kubo, Y., Mann, D. J., Ohmura, M., Hirao, A., Saya, H., et al. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200904105 · Cited by 172
“Bisulfite sequencing analysis was performed as described previously (Suzuki et al., 2006). et al., 2002; Terzian et al., 2008) and why the combination of p53 and p16Ink4a loss frequently occurred in human cancer cells (Malumbres and Barbacid, 2001).”
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X. (2013) · Oncogene · doi:10.1038/onc.2012.81 · Cited by 153
Pant, V., Xiong, S., Iwakuma, T., Quintás-Cardama, A., & Lozano, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102241108 · Cited by 134
Self-citationAcquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Nishikawa, S., & Iwakuma, T. (2023) · Cancers · doi:10.3390/cancers15020429 · Cited by 115
Self-citationHDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis
Ryu, H.-W., Shin, D.-H., Lee, D. H., Choi, J., Han, G., Lee, K. Y., & Kwon, S. H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.033 · Cited by 82
Pharmacological reactivation of p53 as a strategy to treat cancer
Zawacka‐Pankau, J., & Selivanova, G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12336 · Cited by 82
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79
Self-citationClonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
Muzumdar, M. D., Dorans, K. J., Chung, K. M., Robbins, R., Tammela, T., Gocheva, V., Li, C. M.-C., & Jacks, T. (2016) · Nature Communications · doi:10.1038/ncomms12685 · Cited by 72
Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42
Metadata
- Authors
- Terzian, T., Suh, Y.-A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S., & Lozano, G.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2008-05-15
- Volume
- 22
- Issue
- 10
- Pages
- 1337-1344
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2098098349
- Cited by
- 357
- References
- 57
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.